Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: a systematic review and meta-analysis
Fruquintinib significantly improves PFS and disease control in refractory mCRC with manageable toxicity. Limitations include heterogeneity across studies, with most conducted in predominantly Chinese cohorts. Further studies should explore optimal combination strategies and biomarker-based selection.
Authors
- Tarun Kumar Suvvari (ORCID: https://orcid.org/0000-0003-0063-0339)
- Jahnavi Udaikumar (ORCID: https://orcid.org/0000-0001-6212-2458)
- Paul E. Oberstein (ORCID: https://orcid.org/0000-0001-5918-6004)
- Sushrut Ingawale (ORCID: https://orcid.org/0000-0002-6938-6672)
- Satwik Kuppili (ORCID: https://orcid.org/0000-0002-5141-0435)
- Abraham Z. Cheloff (ORCID: https://orcid.org/0000-0002-5489-4789)
- Amulya Bellamkonda
- Vindhya Vasini Lella (ORCID: https://orcid.org/0009-0009-4132-7011)
- Rithish Nimmagadda (ORCID: https://orcid.org/0009-0008-6415-7724)
- Suprabhat Giri
- Aasma Shaukat
Institutions
- Dr. NTR University of Health Sciences (IN)
- Institute of Medical Sciences (IN)
- New York University (US)
Publication Details
- Journal
- Journal of Gastrointestinal Oncology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.21037/jgo-2025-385
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00